Shares of X-Energy surged 6.3% to $19.74 on July 2, extending a rebound from near its 52-week low, after UBS cut its price target but kept faith in the advanced nuclear company's long-term story. UBS lowered its price target to $34 from $40 while maintaining a Buy rating. The paradox — a lower target sparking a rally — tells you everything about where sentiment stands: investors had priced in something far worse.

• Higher Costs Are Real, But the Street Already Knew That. UBS raised its operating expense estimates for 2026 to reflect higher expected cash burn as X-Energy accelerates construction and hiring for its fuel fabrication facility. That matters because first-quarter losses hit $7.57 per share, with net loss widening 252% year-over-year to $166.2 million. The company is burning cash fast to build out its nuclear fuel plant, and every dollar of overspend delays breakeven. But with the stock already down 37% in six months, trading near its 52-week low of $17.37, much of this pain was baked in.

• Wall Street Is Split, and That's the Opportunity. UBS kept its Buy based on X-Energy's strong customer commitments, speed-to-market advantage, and federal cost-share funding.

TD Cowen reiterated Buy at $35, calling it their 2026 Best Smid-Cap Idea. But Jefferies slashed its target to just $22 with a Hold, citing competitive threats and a shrinking valuation premium. The average analyst target of roughly $38.71 still implies over 90% upside — a gap that screams either deep conviction or deep uncertainty.

• The IPO Hangover and a Lockup Cliff Loom Large. X-Energy raised about $1.1 billion from its April 2026 IPO to fund commercialization. But the September 1 lockup expiry — when insiders can sell — is the key near-term technical risk, with analysts flagging a potential 4–8 week drawdown. Value-focused buyers stepping in now are betting they can ride the rebound before that wave of supply hits.

• The Backlog Is Impressive; Revenue Is Not — Yet. X-Energy claims $2 billion in liquidity and an 11.5 GW backlog. But revenue growth remains tied to Department of Energy grants, not diversified commercial streams.

Q1 revenue of $43.4 million missed estimates of $75.85 million by nearly 43%. Until reactor orders start converting to real recurring revenue, the stock trades on faith — and at $19.74, the market is testing how much faith is left.